- CAR T Cell Immunotherapy Beyond Haematological Malignancy
-
Hupperetz C, Lah S, Kim H, Kim CH
- KMID: 2536237
- Immune Netw.
- 2022 Feb;22(1):e6.
- doi: 10.4110/in.2022.22.e6
Chimeric antigen receptor (CAR) T cells, which express a synthetic receptor engineered to target specific antigens, have demonstrated remarkable potential to treat haematological malignancies. However, their transition beyond haematological malignancy... -
- CITED
-
- Close
- SHARE
-
- Close
